Brief: Paxmedica Completes Hat-301 Registrational Trial For Pax-101
01/06/2023 13:40
June 1 (Reuters) - PaxMedica Inc PXMD.O :
* PAXMEDICA COMPLETES HAT-301 REGISTRATIONAL TRIAL FOR
PAX-101
* PAXMEDICA INC - TOP LINE RESULTS PLANNED FOR RELEASE IN
JULY
2023
Source text for Eikon: ID:nGNX4BJGrJ
Further company coverage: PXMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering